These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 26423833)

  • 1. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 8. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study.
    Hilhorst N; Spanoudi-Kitrimi I; Goemans N; Morren MA
    Eur J Pediatr; 2019 Feb; 178(2):253-258. PubMed ID: 30448867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.
    Sheikh O; Yokota T
    Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense drug discovery and development.
    Yamamoto T; Nakatani M; Narukawa K; Obika S
    Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmacokinetics of 2'-
    Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J
    Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
    Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
    Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S; Ozasa S; Yoshioka K; Fujii I; Mitsui K; Nomura K; Kosuge H; Endo F; Matsukura M; Kimura S
    Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
    Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
    Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line.
    Dowling JJ
    Nat Rev Neurol; 2016 Dec; 12(12):675-676. PubMed ID: 27857122
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.